13.04.2025, 2391 Zeichen

Marinomed: Marinomed Biotech AG announced that the Austrian distribution partner Sigmapharm has launched the moisturizing eye drops under the trade name “Coldamaris protect” further to a license deal signed in 2023. The eye drops complement the existing Carragelose over-the-counter (OTC) product portfolio consisting of nasal sprays and throat products for the prophylaxis and treatment of viral respiratory diseases. In a clinical study conducted in Spain in 2024, the eye drops improved dry-eye related symptoms by remarkable 54% while being well tolerated by patients with mild to moderate dry eye syndrome. In 2024, the Carragelose business has been sold to the French Company Unither Pharmaceuticals. Marinomed now supports Unither in transferring the business and successfully continuing the growth of the portfolio. The launch of the eye drops is an important milestone for reaching contractually agreed milestones regarding the earn-out components of the contract.
Marinomed Biotech: weekly performance: -1.85%

UBM: UBM Development AG closed the 2024 financial year with solid liquidity of €199.5m. These results were substantially supported by a fourfold year-on-year increase in apartment sales and the successful sale of non-strategic assets. Against the backdrop of ongoing market challenges in the real estate sector, the loss before tax was reduced to – €23.2m (- €39.4m in 2023). “We say what we do, and we do what we say“ emphasised Thomas G. Winkler, CEO of UBM Development AG, and continued “Our promise for 2024 was liquidity over profitability, and that is what we delivered“. UBM expects a return to the profit zone during the second half of 2025.
UBM: weekly performance: 1.29%

FACC: After FACC fell victim to a fraud case at the end of 2015 (Fake President Incident), around EUR 10.8 million of these funds were frozen in Chinese accounts at the beginning of 2016 thanks to intensive cooperation between Chinese and Austrian authorities. These funds were transferred to the Higher Regional Court of Vienna in 2019 and have now been refunded to FACC after approximately 6 years of proceedings and extensive legal clarifications. As the frozen funds were booked as receivables, the receipt of the funds does not affect earnings, but increases liquidity.
FACC: weekly performance: 8.93%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (10/04/2025)

Christian Drastil: Wiener Börse Plausch

Börsepeople im Podcast S22/17: Thomas Hahn

Bildnachweis

Aktien auf dem Radar:VIG, Kapsch TrafficCom, UBM, EuroTeleSites AG, Flughafen Wien, Palfinger, ATX, ATX Prime, ATX TR, ATX NTR, Bawag, Andritz, Mayr-Melnhof, Telekom Austria, RBI, voestalpine, SBO, Frequentis, Pierer Mobility, BKS Bank Stamm, Oberbank AG Stamm, Warimpex, Amag, EVN, CPI Europe AG, Lenzing, Österreichische Post, RHI Magnesita.

---